ViiV Healthcare announces new collaboration with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1

ViiV Healthcare today announced that they have entered into an agreement with Janssen R&D Ireland Ltd (Janssen) for the development and commercialisation of a single-tablet combining dolutegravir (Tivicay) and Janssen’s non-nucleoside reverse transcriptase inhibitor rilpivirine (Edurant).

Source: GSK news - June 12, 2014 Category: Pharmaceuticals Source Type: news